A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins - PubMed (original) (raw)
Comparative Study
. 2007 Dec;25(12):3093-100.
doi: 10.1634/stemcells.2007-0525. Epub 2007 Aug 23.
Affiliations
- PMID: 17717064
- DOI: 10.1634/stemcells.2007-0525
Comparative Study
A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins
Ryan Reca et al. Stem Cells. 2007 Dec.
Abstract
Complement (C) and innate immunity emerge as important and underappreciated modulators of mobilization of hematopoietic stem/progenitor cells (HSPC). We reported that (a) C becomes activated in bone marrow (BM) during granulocyte-colony-stimulating factor (G-CSF)-induced mobilization by the classic immunoglobulin (Ig)-dependent pathway and that (b) C3 cleavage fragments increase the responsiveness of HSPC to a stromal derived factor-1 gradient. Since patients suffering from severe combined immunodeficiency (SCID) mobilize poorly, we hypothesized that this could be directly linked to the lack of C activating Ig in these patients. In the current study to better elucidate the role of C activation in HSPC mobilization, we mobilized mice that lack Ig (RAG2, SCID, and Jh) by G-CSF or zymosan, compounds that activate C by the classic Ig-dependent and the alternative Ig-independent pathways, respectively. In addition, we evaluated mobilization in C5-deficient animals. Mobilization was evaluated by measuring the number of colony-forming unit-granulocyte macrophage and leukocytes circulating in peripheral blood. We found that (a) G-CSF- but not zymosan-induced mobilization was severely reduced in RAG2, SCID, and Jh mice; (b) impaired G-CSF-induced mobilization was restored after infusion of purified wild-type Ig; and (c) mobilization was severely reduced in C5-deficient mice. These data provide strong evidence that the C system plays a pivotal role in mobilization of HSPC and that egress of HSPC from BM occurs as part of an immune response. Disclosure of potential conflicts of interest is found at the end of this article.
Similar articles
- A pivotal role of activation of complement cascade (CC) in mobilization of hematopoietic stem/progenitor cells (HSPC).
Ratajczak MZ, Wysoczynski M, Reca R, Wan W, Zuba-Surma EK, Kucia M, Ratajczak J. Ratajczak MZ, et al. Adv Exp Med Biol. 2008;632:47-60. Adv Exp Med Biol. 2008. PMID: 19025113 Review. - A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
Kiss J, Kunstár A, Fajka-Boja R, Dudics V, Tóvári J, Légrádi A, Monostori E, Uher F. Kiss J, et al. Exp Hematol. 2007 Feb;35(2):305-13. doi: 10.1016/j.exphem.2006.09.015. Exp Hematol. 2007. PMID: 17258079 - [The role of stromal cell-derived factor and its receptor-CXCR4 in G-CSF-induced hematopoietic stem cell mobilization].
Jin FY, Qiu LG, Li QC, Meng HX, Wang YF, Yu Z, Li Q, Han JL. Jin FY, et al. Zhonghua Xue Ye Xue Za Zhi. 2007 Feb;28(2):98-102. Zhonghua Xue Ye Xue Za Zhi. 2007. PMID: 17650669 Chinese. - Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties.
Pelus LM, Fukuda S. Pelus LM, et al. Exp Hematol. 2006 Aug;34(8):1010-20. doi: 10.1016/j.exphem.2006.04.004. Exp Hematol. 2006. PMID: 16863907 Review.
Cited by
- Variation in mesenchymal KITL/SCF and IGF1 expression in middle age underlies steady-state hematopoietic stem cell aging.
Young KA, Telpoukhovskaia MA, Hofmann J, Mistry JJ, Kokkaliaris KD, Trowbridge JJ. Young KA, et al. Blood. 2024 Jul 25;144(4):378-391. doi: 10.1182/blood.2024024275. Blood. 2024. PMID: 38598841 - Platelet-derived circulating soluble P-selectin is sufficient to induce hematopoietic stem cell mobilization.
Wang TF, Liou YS, Yang SH, Lin GL, Chiang YW, Lien TS, Li CC, Wang JH, Chang HH, Sun DS. Wang TF, et al. Stem Cell Res Ther. 2023 Oct 20;14(1):300. doi: 10.1186/s13287-023-03527-w. Stem Cell Res Ther. 2023. PMID: 37864264 Free PMC article. - Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors.
Porfyriou E, Letsa S, Kosmas C. Porfyriou E, et al. World J Clin Oncol. 2021 Sep 24;12(9):746-766. doi: 10.5306/wjco.v12.i9.746. World J Clin Oncol. 2021. PMID: 34631440 Free PMC article. Review. - Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization.
Bisht K, McGirr C, Lee SY, Tseng HW, Fleming W, Alexander KA, Matsumoto T, Barbier V, Sims NA, Müller-Newen G, Winkler IG, Bonig H, Lévesque JP. Bisht K, et al. Leukemia. 2022 Feb;36(2):333-347. doi: 10.1038/s41375-021-01413-z. Epub 2021 Sep 13. Leukemia. 2022. PMID: 34518644 - HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR.
Bisht K, Brunck ME, Matsumoto T, McGirr C, Nowlan B, Fleming W, Keech T, Magor G, Perkins AC, Davies J, Walkinshaw G, Flippin L, Winkler IG, Levesque JP. Bisht K, et al. Blood Adv. 2019 Feb 12;3(3):406-418. doi: 10.1182/bloodadvances.2018017566. Blood Adv. 2019. PMID: 30733301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous